{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Tasisulam_Sodium",
  "nciThesaurus": {
    "casRegistry": "519055-63-1",
    "chebiId": "",
    "chemicalFormula": "C11H5BrCl2NO3S2.Na",
    "definition": "The sodium salt of an acyl-sulfonamide with potential antineoplastic activity. Selectively toxic towards tumor cells, tasisulam appears to induce tumor cell apoptosis by a mitochondrial-targeted mechanism involving the loss of mitochondrial membrane potential and induction of reactive oxygen species (ROS). In combination with an angiogenesis inhibitor, this agent may exhibit synergistic antiangiogenic activity.",
    "fdaUniiCode": "O3955SHR9J",
    "identifier": "C88304",
    "preferredName": "Tasisulam Sodium",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C177298"
    ],
    "synonyms": [
      "Benzamide, N-[(5-Bromo-2-thienyl)sulfonyl]-2,4-dichloro-, Sodium Salt",
      "LY-573636.Na",
      "LY573636-Sodium",
      "TASISULAM SODIUM",
      "Tasisulam Sodium"
    ]
  }
}